NICE published costing statement for its guidance on ranibizumab for diabetic macular oedema

Source: NICE
Area: News
NICE has published guidance recommending against the use of ranibizumab within the NHS for the treatment of visual impairment due to diabetic macular oedema (TAG 237; see link below).    A costing statement published alongside this notes that an estimated 23,000 to 70,000 adults in England may need treatment for diabetic macular oedema (this may be an underestimate as it is based on the number of people diagnosed with diabetes).  The estimated cost of treatment with ranibizumab for this indication is around £13,000 per person over (Read more...)

Full Story →